{"entity":{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","aka":[],"tldr":"Cogent Biosciences makes bezuclastinib, a pill that blocks a mutated protein called KIT. It is being tested in a rare gut tumour called GIST and in systemic mastocytosis, a disease of overactive immune cells.","summary":"Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor of KIT D816V and other KIT mutations. In November 2025 it reported positive top-line SUMMIT results in non-advanced systemic mastocytosis (FDA Breakthrough Therapy designation; NDA planned for year-end 2025) and awaited the phase 3 PEAK trial of bezuclastinib plus sunitinib in second-line gastrointestinal stromal tumours (GIST) and the registration-directed APEX trial in advanced systemic mastocytosis. Preclinical programmes include a JAK2 V617F mutant-selective inhibitor, a pan-KRAS(ON/OFF) inhibitor, and selective ErbB2 (HER2), PI3K-alpha and FGFR2 inhibitors. Cogent (formerly Unum Therapeutics) trades on Nasdaq as COGT and reported about 430 million US dollars pro forma cash in November 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cogentbio.com/"},{"label":"Pipeline and publications","url":"https://www.cogentbio.com/pipeline-publications/"},{"label":"Q3 2025 results and business update (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm"},{"label":"December 2020 public offering 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312520308501/d72504d8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit","her2","kras","pik3ca","fgfr2"],"drugs":["bezuclastinib","cgt4859"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05186753","nct04996875","nct06777316"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PEAK and APEX results (expected November and December 2025) were not verified."],"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.cogentbio.com/","ticker":"COGT","stage":"public","investors":[],"funding":[]},"route":"/companies/cogent-biosciences/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/"},{"id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/"}],"trial":[{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/"},{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/"},{"id":"nct05186753","kind":"trial","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","route":"/trials/nct05186753/"},{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/"}]}}